170 results on '"Tan, David S. P."'
Search Results
2. Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials
3. PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production
4. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
5. Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer – International considerations amongst upper middle- and high-income countries (UMIC and HIC)
6. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
7. Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit.
8. Current practices and challenges in genetic testing and counseling for women with breast and ovarian cancer in Asia.
9. Correction: PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production
10. Targeting the immune microenvironment for ovarian cancer therapy.
11. Transcoelomic Metastasis
12. Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma
13. Closing the gap for cervical cancer research in Vietnam: current perspectives and future opportunities: a report from the 5th Gynecologic Cancer InterGroup (GCIG) Cervical Cancer Research Network (CCRN) Education Symposium.
14. Proportions and incidence of locally advanced cervical cancer: a global systematic literature review
15. Transcoelomic Metastasis
16. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
17. Transcoelomic Metastasis
18. Ovarian Cancer: Can We Reverse Drug Resistance?
19. Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial.
20. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
21. Editorial: Harnessing DNA Damage Response in Gynecologic Malignancies
22. The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives
23. Lipidomic Analysis of Archival Pathology Specimens Identifies Altered Lipid Signatures in Ovarian Clear Cell Carcinoma
24. Transcoelomic Metastasis
25. Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
26. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers
27. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
28. Combined modality management of advanced cervical cancer including novel sensitizers.
29. Appraising iniparib, the PARP inhibitor that never was—what must we learn?
30. Getting it right: designing microarray (and not ‘microawry’) comparative genomic hybridization studies for cancer research
31. Weekly paclitaxel in the treatment of recurrent ovarian cancer
32. Ovarian clear cell adenocarcinoma: a continuing enigma
33. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore.
34. A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01).
35. A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
36. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
37. Biomarkers for Homologous Recombination Deficiency in Cancer
38. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
39. Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
40. Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study.
41. Transcoelomic Metastasis
42. Microarray-Based Comparative Genomic Hybridization
43. Ovarian Cancer: Can We Reverse Drug Resistance?
44. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
45. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers
46. Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?
47. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
48. Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation
49. Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement.
50. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.